There’s no shortage of headlines and hypotheticals about the blockbuster drug class of GLP-1s. Stephen Klasko, MD, argues we’re asking the wrong questions about GLP-1s.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
The GLP-1 questions facing health systems
